In addition, there was a significantly strong and negative correlation between JAK2 gene levels after 3 months of imatinib therapy and the presence of CHR (r = −0.605, p < 0.001) in patients with chronic phase CML. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.